Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for $3.05bn in cash. This…
29 Dec 2025
Sanofi buys hep B vaccine maker for $2.2bn
Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's pipeline amid significant vaccine policy changes in the US. The…
29 Dec 2025
Revamping best-selling drugs to combat patent cliff has limits
As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making moves to try and reduce the impact. Patent expiry is…
29 Dec 2025
Innovent receives NMPA approval for Tabosun colon cancer treatment
Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application (NDA) for Tabosun (ipilimumab N01 injection), a CTLA-4 monoclonal antibody for colon cancer. The…
26 Dec 2025
Gilead Sciences to acquire Repare’s RP-3467
Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467. The transaction involves a total consideration of up to $30m to Repare and directly…
24 Dec 2025
Zydus and Bioeq partner for commercialisation of Nufymco in US
Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq for the US commercialisation of Vascular Endothelial Growth Factor (VEGF) inhibitor Nufymco, an interchangeable biosimilar…
23 Dec 2025
Ipsen outlays $1bn for China-based Simcere’s preclinical ADC
Ipsen has added a Chinese-developed antibody drug conjugate (ADC) to its pipeline in a deal that could top $1bn, cementing the anti-tumour modality’s status as one of the standout performers…